We previously found a higher number of spike-specific IFNγ+, IL-2+, and polyfunctional IFNγ+/IL-2+ T-cells, with enhanced proliferative capacity, in aCD20-MS patients compared to a control group after primary vaccination series with two doses of mRNA-based COVID-19 vaccines (57). This evidence concerns the gene IL2 and myeloid sarcoma.